期刊文献+

121例肠道原发性淋巴瘤临床病理分析 被引量:12

Clinicopathological analysis of primary intestinal lymphoma:a report of 121 cases
下载PDF
导出
摘要 目的研究肠道原发性淋巴瘤的临床病理特点和预后。方法复习121例肠道原发性淋巴瘤临床资料、大体所见、HE切片、免疫组化染色,按2008年WHO造血与淋巴组织肿瘤分类重新进行分类,并用Kaplan-Meier法进行生存分析。结果121例肠道原发性淋巴瘤发病年龄从7~81岁,平均年龄52.7岁,中位年龄55岁。男性88例,女性33例,男女比例8∶3。发病部位分别为大肠(结、直肠)62例(51.2%),小肠(空、回肠)47例(38.8%),十二指肠7例(5.8%),多发部位4例(3.3%),阑尾1例(0.8%)。临床上以腹痛、腹胀(72.9%)、下消化道出血(22.0%)、发热(10.2%)、腹部包块(8.5%)、腹泻(8.5%)、消瘦(5.1%)等为首发症状。大体上表现为隆起型(37.3%)、溃疡型(33.9%)和浸润型(28.8%)。组织学类型分别为弥漫性大B细胞淋巴瘤,非特殊类型68例(56.2%),MALT淋巴瘤18例(14.9%),外周T细胞淋巴瘤,非特殊类型13例(10.7%),肠病相关T细胞淋巴瘤7例(5.8%),结外NK/T细胞淋巴瘤,鼻型4例(3.3%),套细胞淋巴瘤和滤泡性淋巴瘤各3例(2.5%),ALK阴性的间变性大细胞淋巴瘤2例(1.7%),慢性淋巴细胞性白血病/小淋巴细胞性淋巴瘤、Burkitt淋巴瘤和不能分类的B细胞淋巴瘤各1例(0.8%)。59例外检病例中共随访39例(66.1%),随访时间1-102月,平均随访时间19.7月,目前死亡15例。20例失访(未回信或拒绝告知)。结论肠道原发性淋巴瘤以中老年男性多见,最常累及的部位是大肠(结、直肠),临床表现以腹痛、腹胀多见;最常见的组织学类型是弥漫性大B细胞淋巴瘤,非特殊类型。肠道原发性T细胞淋巴瘤的预后比B细胞淋巴瘤差。 Objective To analyze the clinicopathological characteristics and prognosis of primary intestinal lymphoma. Methods The clinical and pathological data of 121 cases of primary intestinal lymphoma were reviewed. The pathology was examined by HE and immunohistochemical staining and reclassified according to the 2008 WHO classification of tumors derived from haematopoietic and lymphoid tissues. The clinical data were analyzed by Kaplan-Meier method. Results The age of patients ranged from 7 to 81 years,with an average of 52.7 years and median of 55 years. The male-to-female ratio was 8 : 3(88 : 33). The most frequent site of the lesions was the large intestine (n=62,51.2%),followed by small intestine (n= 47,38.8%),duodenum (n= 7, 5.8%),multiple intestinal sites (n=4, 3.3%) and appendix (n= 1,0.8%). The clinical presentations included abdominal pain and/or distention (72.9%); lower digestive tract hemorrhage (22.0%), fever (10.2%),abdominal mass (8.5%), diarrhea (8.5%) and weight loss (5. 1%). The major gross findings were bossing (37.3%),ulcer (33.9%) and infiltrating (28.8%). The diagnoses were: not specified diffuse large B-cell lymphoma (68/ 121,56.2% ) ,MALT Iymphoma (18/121,14.9%) ,not specified peripheral T-cell lymphoma (13/121,10.7%) ,enteropathy- associated T-cell lymphoma (7/121,5.8 % ), extranodal NK/T cell lymphoma, nasal-type (4/121,3.3 % ), mantle cell lymphoma (3/121,2.5%),follicular lymphoma (3/121,2.5%),anaplastic large ceil lymphoma,ALK-negative (2/121,1.7%),chronic lymphocytic leukemia /small lymphocytic lymphoma (1/121,0.8%),Burkitt lymphoma (1/121,0.8%) and unclassifiable B- cell lymphoma (1/121, 0.8%). The follow-up time of 39 cases was 1-102 month with an average of 19.7 months. Conclusions Primary intestinal lymphoma can usually be found in mid-aged and elderly males. Large intestine (colon, rectum) is the most common site involved. Abdominal pain and/or distention are the common clinical manifestations. Diffuse large B-cell lymphoma ,not otherwise specified is the most common histological type. Compared with B-cell lymphoma ,primary intestinal T-cell lymphoma has a worse prognosis.
出处 《实用肿瘤杂志》 CAS 北大核心 2009年第4期353-357,共5页 Journal of Practical Oncology
关键词 淋巴瘤/病理学 肠肿瘤/病理学 免疫组织化学 预后 lymphoma/pathology intestinal neoplasms/pathology immunohistochemistry prognosis
  • 相关文献

参考文献15

  • 1d'Amore F,Brincker H,Christensen BE,et al.Non-Hodgkin's lymphoma in the elderly.A study of 602 patients aged 70 or older from a Danish population-based registry.The Danish LYEO-study Group[J].Ann Oncol,1992,3(5):379-386.
  • 2d'Amore F,Brincker H,Gronbaek K,et al.Non-Hodgkin's lymphoma of the gastrointestinal tract:a population-based analysis of incidence,geographic distribution,clinicopathologic presentation features,and prognosis[J].J Clin Oncol,1994,12(8):1673-1684.
  • 3Dawson IM,Cornes JS,Morson BC.Primary malignant lymphoid tumors of the intestinal tract.Report of 37 cases with a study of factors influencing prognosis[J].Br J Surg,1961,49(1):80-89.
  • 4Swerdlow SH,Campo E,Harris NL,et al.WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues[M].Lyon:LARC Press,2008:9-15.
  • 5Kohno S,Ohshima K,Yoneda S,et al.Clinicopathological analysis of 143 primary malignant lymphomas in the small and large intestines based on the new WHO classification[J].Histopathology,2003,43(2):135-143.
  • 6Andhavarapu S,Tolentino AM,Jha C,et al.Diffuse large B-cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract[J].Clin Lymphoma Myeloma,2008,8(3):179-183.
  • 7Michopoulos S,Petraki K,Matsouka C,et al.Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract[J].J Clin Oncol,2008,26(9):1555-1557.
  • 8王焱,周晓军.弥漫性大B细胞淋巴瘤[J].医学研究生学报,2006,19(3):277-280. 被引量:9
  • 9Rosenwald A,Wright G,Chan WC,et al.The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma[J].N Engl J Med,2002,346(25):1937-1947.
  • 10Hans CP,Weisenburger DD,Greiner TC,et al.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J].Blood,2004,103(1):275-282.

二级参考文献59

  • 1杨继红,于亚平.B细胞淋巴瘤分子发病机制的研究进展[J].医学研究生学报,2005,18(2):167-170. 被引量:9
  • 2张雅洁,李玉林,朱桂彬,张丽红.胃肠道原发非何杰金淋巴瘤病理及免疫组化研究[J].白求恩医科大学学报,1994,20(3):224-226. 被引量:1
  • 3包悍英,王云贵,沈朋,方维佳,张晓琛,徐农,蔡真.骨髓凋亡蛋白抑制因子survivin检测在非霍奇金淋巴瘤中的临床意义[J].实用肿瘤杂志,2007,22(2):160-162. 被引量:1
  • 4Waters JS,Webb A,Cunningham D,et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin's lymphoma [J]. J Clin Oncol, 2000, 18 (9): 1812- 1823.
  • 5Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma [J]. Lancet, 1997,349 (9059) : 1137- 1141.
  • 6O'Connor OA, Smith EA, Toner LE, et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide [J]. Clin Cancer Res, 2006,12 (9) : 2902- 2911.
  • 7Mitchell SR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts [J]. Mol Cancer Ther, 2004, 3 (12) : 1693-1699.
  • 8Williams SA,Chang L,Buzby JS,et al. Cationic lipids reduce time and dose of c-mye antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth [J]. Leukemia, 1996, 10(12) : 1980-1989.
  • 9Hermeking H. The MYC oncogene as a cancer drug target [J]. Curr Cancer Drug Targets,2003,3(3):163 -175.
  • 10Kanwar JR,Shen WP,Kanwar RK,et al. Effects of survivin antagonists on growth of established tumors and BT-1 immunogene therapy [J]. J Natl Cancer Inst, 2001,93(20) : 1541-1552.

共引文献67

同被引文献85

引证文献12

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部